Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel bought 2,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $11.97 per share, with a total value of $23,940.00. Following the completion of the transaction, the chief executive officer now owns 5,543,702 shares of the company’s stock, valued at $66,358,112.94. The trade was a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Snehal Patel also recently made the following trade(s):
- On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $11.12 per share, for a total transaction of $35,584.00.
Greenwich LifeSciences Stock Performance
Shares of NASDAQ:GLSI opened at $13.11 on Tuesday. The firm has a fifty day moving average of $13.18 and a 200 day moving average of $14.15. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The firm has a market capitalization of $172.33 million, a PE ratio of -16.39 and a beta of 1.66.
Hedge Funds Weigh In On Greenwich LifeSciences
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
See Also
- Five stocks we like better than Greenwich LifeSciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- What is the Dogs of the Dow Strategy? Overview and Examples
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Investing in Commodities: What Are They? How to Invest in Them
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.